Payment overview · 2025
General Payments
$104.23
6 reported records · 6 companies
Healthcare provider profile · identity verified
Brent Austin Webb, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OWENSBORO, KY · NPI 1316406176
Verified facts
What the public records show
CMS Open Payments records show Brent Austin Webb, MD received $104.23 in general payments during 2025 across 6 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.57 | 20.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.38 | 19.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.32 | 17.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.30 | 14.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.15 | 14.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.51 | 13.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $104.23 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 144 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 252 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 58 |
| Gabapentin | Gabapentin | 174 | 41 |
| Lisinopril | Lisinopril | 168 | 50 |
| Trazodone Hcl | Trazodone Hcl | 154 | 45 |
| Losartan Potassium | Losartan Potassium | 152 | 46 |
| Ozempic | Semaglutide | 144 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 141 | 46 |
| Potassium Chloride | Potassium Chloride | 134 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 131 | 30 |
| Montelukast Sodium | Montelukast Sodium | 127 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 25 |
| Omeprazole | Omeprazole | 114 | 31 |
| Furosemide | Furosemide | 111 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 25 |
| Metformin Hcl | Metformin Hcl | 101 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 25 |
| Famotidine | Famotidine | 92 | 26 |
| Metformin Hcl Er | Metformin Hcl | 84 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 27 |
| Jardiance | Empagliflozin | 82 | 20 |
| Carvedilol | Carvedilol | 81 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 20 |
| Bupropion Xl | Bupropion Hcl | 74 | 24 |
| Meloxicam | Meloxicam | 70 | 29 |
| Allopurinol | Allopurinol | 69 | 20 |
| Simvastatin | Simvastatin | 64 | 15 |
| Ondansetron Odt | Ondansetron | 63 | 23 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 61 | 17 |
| Ezetimibe | Ezetimibe | 61 | 13 |
| Farxiga | Dapagliflozin Propanediol | 60 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 14 |
| Promethazine Hcl | Promethazine Hcl | 55 | 12 |
| Sertraline Hcl | Sertraline Hcl | 54 | 18 |
| Atenolol | Atenolol | 52 | 15 |
| Baclofen | Baclofen | 51 | suppressed |
| Fenofibrate | Fenofibrate | 51 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 25 |
| Mounjaro | Tirzepatide | 48 | 11 |
| Celecoxib | Celecoxib | 47 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 16 |
| Eliquis | Apixaban | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | 12 |
| Alprazolam | Alprazolam | 41 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 40 | suppressed |
| Topiramate | Topiramate | 39 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 30 |
| Methocarbamol | Methocarbamol | 33 | 13 |
| Finasteride | Finasteride | 31 | suppressed |
| Prednisone | Prednisone | 31 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 28 |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 28 |
| Risperidone | Risperidone | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 20 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 14 |
| Glipizide | Glipizide | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | 11 |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Permethrin | Permethrin | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Actemra | Tocilizumab | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $104.23 · 6 records | Otsuka America Pharmaceutical, Inc. | AREXVY, Cologuard Collection Kit, EVENITY, Omnipod, Ozempic, PROLIA, REXULTI, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error